Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by juniper88on Jul 11, 2019 3:08pm

62 Views

Post# 29909971

RE:RE:RE:RE:RE:RE:RE:Luc: HIV NASH 8-10x current Egrifta market

scarlet1967 wrote: The way I undresrand it the Trogarzo sales was equivalent to Egrifta in June as it was 20% increase from May to June, they don't give monthly sale reports for all we know Q2 sales for Tragazo was 7 mil and Egrifta 9 mil so in June say for arguments sake both drugs sold 3 mil.
The 20% increase was on a month to month basis so the quarter to quarter increase could well be higher if the trend continues.

They said 20% increase from first 5 weeks of Q2 compared to first 5 weeks of Q3

Bullboard Posts

Pro Women’s Hockey League comes to NHL 25 in December